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Summary. Epoetin beta, three-times weekly (t.i.w.), is
effective in reversing anaemia in lymphoproliferative disor-
ders. The current study investigated whether an epoetin
beta dose of 30 000 IU given subcutaneously once weekly
(q.w.) was at least as effective as 10 000 t.i.w. administra-
tion in anaemic patients with lymphoproliferative malig-
nancy and defective endogenous erythropoietin (Epo)
production. Overall, 241 anaemic patients with multiple
myeloma, low-grade non-Hodgkin’s lymphoma or chronic
lymphocytic leukaemia, all with serum Epo values
£100 mU/ml, were randomized to receive the q.w.
(n ¼ 119) or t.i.w. (n ¼ 122) regimen for 16 weeks. The
primary efficacy criterion, i.e. the time-adjusted area under
the haemoglobin–time curve from weeks 5–16, was com-
parable between the q.w. and t.i.w. groups [differ-
ence ¼ )0Æ20 g/dl (90% confidence interval )0Æ52–0Æ11)].
Moreover, response rates were high and similar in both
arms (72% vs 75%, q.w. and t.i.w. groups respectively).
Baseline serum Epo was predictive of response: the lower
serum Epo, the higher the likelihood of response
(P ¼ 0Æ002). Thus, epoetin beta administered q.w. is an
effective and convenient treatment for anaemia in patients
with lymphoproliferative disorders. Tailoring this treatment
modality to subjects with defective endogenous Epo pro-
duction represents a rational use of epoetin from both a
medical and a community perspective.
Keywords: anaemia, erythropoietin, chronic lymphocytic
leukaemia, non-Hodgkin’s lymphoma, multiple myeloma.
Recombinant human Epo (rHuEpo, or epoetin) is remark-
ably effective and well tolerated in the treatment of anaemic
patients with defective production of the endogenous
hormone. This is particularly true for uraemia, which
represents the prototype of Epo deficiency, so that the
treatment of this condition is currently considered the gold
standard of epoetin use (Tong & Nissenson, 2001).
Erythropoietin production, however, is reduced in several
other conditions, which include anaemia secondary to
malignant disorders or as a result of their treatment
(Cazzola et al, 1997). Based on a systematic review of the
literature, the recent guidelines of the American Society of
Clinical Oncology and the American Society of Hematology
(Rizzo et al, 2002) recommend use of epoetin as a treatment
option for patients with chemotherapy-associated anaemia
with a haemoglobin concentration below 10 g/dl, and
advise subcutaneous administration thrice weekly at a
starting dose of 150 U/kg.
Three European trials in the last few years have studied
the efficacy of epoetin beta in anaemic patients with
multiple myeloma, non-Hodgkin’s lymphoma and chronic
lymphocytic leukaemia, most of whom were receiving
concurrent or recent chemotherapy for their disease
(Cazzola et al, 1995; Osterborg et al, 1996, 2002). Despite
considerable differences in their designs, all three studies
showed that defective endogenous Epo production was a
major predictor of response to treatment. In particular,
Osterborg et al (2002) demonstrated that epoetin beta
treatment was effective in relieving anaemia and improving
quality of life in severely anaemic, transfusion-dependent
patients with a low serum Epo concentration. These
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observations have reinforced the concept that epoetin
treatment is primarily effective in the treatment of endog-
enous Epo deficiency.
Although effective, the conventional regimen of thrice-
weekly (t.i.w.) subcutaneous administration of epoetin is
costly and cumbersome, and there is a need for improve-
ment (Bunn, 2002). In stable haemodialysis patients,
subcutaneous administration of epoetin beta once weekly
(q.w.) has been shown to be as safe and effective in
maintaining haemoglobin levels as a t.i.w. schedule (Weiss
et al, 2000; Locatelli et al, 2002). As regards cancer
patients, an uncontrolled, non-randomized, community-
based study employing epoetin alpha at a dose of 40 000 IU
q.w. has reported improvements in haemoglobin and
quality of life similar to the conventional t.i.w. dosing
(3 · 10 000 IU) (Gabrilove et al, 2001).
In order to properly assess the effectiveness of a once-
weekly dosing regimen in the epoetin treatment of anaemic
patients with lymphoproliferative malignancy, we conduc-
ted a prospective randomized trial comparing the efficacy
and safety of subcutaneous epoetin beta 30 000 IU q.w. vs
10 000 IU t.i.w. in individuals with evidence of defective
endogenous Epo production, as indicated by low serum Epo
levels.
PATIENTS AND METHODS
The present study was an open-label, randomized, parallel-
group, multicentre, phase III trial conducted between
September 2000 and December 2001 at 51 centres in 12
countries, promoted and supported by F. Hoffmann–La
Roche Ltd, Basel, Switzerland. The design and conduct of
the study complied with the ethical principles of good
clinical practice, in accordance with the Declaration of
Helsinki and local legal requirements. The study was
approved by an independent ethics committee at each
centre; all patients provided written informed consent before
enrolment.
Patients. Adult patients (‡18 years) eligible for study
inclusion had a histologically confirmed diagnosis of low-
grade non-Hodgkin’s lymphoma (NHL), multiple myeloma
(MM) or chronic lymphocytic leukaemia (CLL), a Hb level of
9–11 g/dl and a serum Epo level £100 mU/ml. If systemic
anticancer therapy was to be given, it was to continue for at
least 4 months from the time of the first study treatment.
Patients also had to have a World Health Organization
(WHO) performance status grade of 0–2 and a life expect-
ancy > 6 months.
Exclusion criteria were: transfusion of red blood cells
during the 2 months prior to the study, therapy-resistant
hypertension, acute or chronic bleeding requiring treatment
in the 3 months prior to study commencement, antitumour
therapy in the week before the screening visit (with the
exception of corticosteroids and/or low-dose chlorambucil),
scheduled bone marrow transplantation during the study
period, functional iron deficiency (transferrin saturation
< 20%) which could not be treated with intravenous (i.v.)
iron supplementation prior to the start of study treatment,
thrombocytopenia or thrombocytosis (platelet count < 50 or
> 450 · 109/l respectively), vitamin B12 or folic acid
deficiencies, haemolysis (haptoglobin < 0Æ30 mg/l), epilepsy,
pregnancy, or lactation.
Study procedures. Patients eligible for study inclusion
were randomized 1:1 [stratified according to malignancy
type, platelet count at screening (< 100 · 109/l,
‡ 100 · 109/l) and study centre] to receive epoetin beta
t.i.w. (10 000 IU per dose) or q.w. (30 000 IU per dose) for
16 weeks, using the RecoPen (F. Hoffmann–La Roche,
Basel, Switzerland) subcutaneous self-injection delivery
system. For patients who failed to respond after 4 weeks of
therapy (as indicated by receipt of a blood transfusion in the
previous week or an increase in Hb of < 0Æ5 g/dl vs
baseline), the dose of epoetin beta was doubled. Thus, the
dose per injection for the t.i.w. group increased to
20 000 IU and the dose for the q.w. group increased to
60 000 IU (administered as 30 000 IU twice weekly).
Conversely, if Hb increased by more than 2 g/dl within
the same period, the dose of study medication was reduced
by 50%. If Hb exceeded 14 g/dl, the study medication was
suspended until Hb declined to £13 g/dl when therapy was
reinstated at 50% of the previous dose. Blood transfusions
were to be avoided at Hb levels > 8Æ5 g/dl unless medically
indicated, e.g. when marked symptoms related to anaemia
such as angina pectoris was present. Haemoglobin was
measured at screening, during the first week of therapy and
every 2 weeks thereafter.
Enrolled patients with a screening transferrin saturation
of < 20% were to receive i.v. iron supplementation to ensure
that adequate iron was rapidly available for erythropoiesis.
Following randomization, iron supplementation was also to
be performed if the transferrin saturation fell below 20%.
The preferred route of administration of supplemental iron
was i.v.; however, if this was not possible, then oral iron
supplementation was given. Adverse events, haematological
parameters, concomitant medications, blood transfusions
and antitumour therapy were documented throughout the
course of the study.
Efficacy assessments. The primary efficacy variable was
the time-adjusted Hb area under the curve between weeks 5
and 16 (Hb AUC5)16). The Hb AUC was determined by the
trapezoid rule, and was then divided by the time interval
from the first Hb measurement to the last Hb measurement
between weeks 5 and 16. All available Hb values were
taken into account, whether they were measured at a
protocol-specified visit or determined immediately preceding
a blood transfusion at non-protocol-specified visits. The Hb
values measured in the 3 weeks following a blood transfu-
sion were replaced by the Hb value measured immediately
before the blood transfusion to correct for the increased Hb
caused by the blood transfusion.
Secondary efficacy parameters included response rate
(defined as an increase in Hb of ‡2 g/dl vs baseline without
blood transfusion in the previous 6 weeks), change in Hb
from baseline, Hb nadir at 4-week intervals, the percentage
of patients with corrected anaemia (Hb nadir ‡11 or 12 g/dl)
at 4-week intervals, transfusion-free or severe anaemia-free
(Hb < 8Æ5 g/dl) survival, and transfusion requirements
(number of patients and units transfused). Various clinical
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parameters were measured with the aim of identifying those
predictive of response to epoetin beta. These parameters
could be divided into those measured at baseline (serum
Epo) and those measured early in the course of treatment
[changes in Hb levels and in soluble transferrin receptor
(sTfR) levels].
Laboratory measurements. Blood counts were obtained
with the use of automated counters. Circulating Epo levels
were measured by a photometric enzyme immunoassay for
the quantitative in-vitro determination of human erythro-
poietin in antibody-precoated microtitre plates (Roche
Diagnostics, Mannheim, Germany). The amount of sTfR
was estimated by an immunoturbidimetric assay using an
automated clinical chemistry analyser (Roche Diagnostics).
In order to detect Epo-specific antibodies in serum, the above
photometric enzyme immunoassay for the quantitative in-
vitro determination of human Epo was employed, adopting
a two-step procedure with a displacement step.
Statistical analysis. We planned to enrol 230 patients
with low-grade NHL, MM or CLL that, with an assumed
loss-to-follow-up rate of 20%, would provide 93 patients
per treatment arm. This would be sufficient to demonstrate
with 80% power (a ¼ 0Æ05) that epoetin beta administered
q.w. is non-inferior to the t.i.w. regimen with respect to the
primary efficacy variable.
The primary efficacy variable was analysed for the intent-
to-treat (ITT) population and the per protocol (PP) popula-
tion (Table I) was analysed using an analysis of covariance
(ancova) model; ‘treatment group’ was the main factor,
with ‘underlying malignant disease’ and ‘baseline Hb
values’ as covariates. Based on the least squares means
and the corresponding standard errors of the ancova model,
90% and 95% confidence intervals were calculated for the
difference in Hb-AUCs between the two treatment groups at
a significance level of 5%.
The time to first response was analysed using the log-
rank test, adjusted for underlying malignant disease. The
response curves were estimated using Kaplan–Meier tech-
niques. Transfusion-free or severe anaemia-free survival
was analysed using a Cox proportional hazard model,
adjusted for the type of underlying malignant disease at a
significance level of 5% (Wald v2 test). The rate of failure
was defined as the first date with Hb < 8Æ5 g/dl, a blood
transfusion or death. Kaplan–Meier methods were used to
estimate the transfusion-free or severe anaemia-free survi-
val curves. Transfusion requirements were compared
between treatment groups with the Cochrane–Maentel–
Haenzel test, unadjusted and adjusted for underlying
malignant disease.
The change from baseline to final Hb value and the Hb
nadir in any 4-week interval was analysed separately using
ancova models with the main factor ‘treatment group’, and
‘underlying malignant disease’ and ‘baseline Hb value’ as
covariates. The influence of various clinical parameters on
response was analysed using Cox’s proportional hazard
models.
RESULTS
Of a total of 322 patients screened for serum Epo, 241 were
found of have levels £100 mU/ml (Table I): these subjects
were enrolled into the study and randomized to the two
treatment groups (q.w., n ¼ 119; t.i.w., n ¼ 122). There
were no major differences in the demographic and baseline
clinical characteristics of the two treatment groups (Table II).
Multiple myeloma was the predominant tumour type in
both groups (70%). The vast majority of patients were
receiving concurrent chemotherapy or had received recent
chemotherapy for their disease: only 6/237 (2Æ5%) subjects
did not receive chemotherapy before or during the study. In
total, 22 patients (9%) were withdrawn from the study
(q.w., n ¼ 14; t.i.w., n ¼ 8). The main reasons for with-
drawal were death (n ¼ 12), adverse events (n ¼ 4) and
refusal of treatment (n ¼ 4).
Increase in haemoglobin over time
Mean baseline Hb values at the start of study treatment
were similar for both groups (Table II). The change in Hb
level over time is depicted in Fig 1. Following 8 weeks of
treatment, median changes in Hb were > 2 g/dl in both
Table I. Patient distribution into the study populations.
Study population
Serum
Epo > 100 mU/ml, n
Serum
Epo £100 mU/ml, n
Screened for serum Epo (n ¼ 322) 81 241
Once-weekly (q.w.), n Thrice-weekly (t.i.w.), n
Randomized (n ¼ 241) – 119 122
Safety (n ¼ 237)* – 118 119
Intent to treat (n ¼ 229) – 115 114
Per protocol (n ¼ 205) – 101 104
*Four patients were excluded from the safety population (q.w., n ¼ 1; t.i.w., n ¼ 3) as they did not receive epoetin beta.
Eight patients were excluded from the intent-to-treat population (q.w., n ¼ 3; t.i.w., n ¼ 5) as they had only one Hb level
measured between weeks 5 and 16.
Twenty-four patients were excluded from the per protocol population for violations of the study criteria (q.w., n ¼ 14;
t.i.w., n ¼ 10).
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treatment groups; the difference between the groups was
0Æ2 g/dl at any time point.
The time-adjusted Hb AUC5)16 was calculated for each
patient in both treatment groups from the PP population.
The median Hb-AUC5)16 was similar in both groups
(differences 0Æ2–0Æ3 g/dl). ancova confirmed that the
median estimates of Hb-AUC5)16 were similar between
the q.w. and t.i.w. groups (12Æ05 vs 12Æ27 g/dl) with the
overall difference being 0Æ22 [)0Æ53, 0Æ10, 90% confidence
interval (CI)]. Differences between the t.i.w. and q.w.
groups did not exceed 0Æ6 g/dl at any time. These data
were confirmed when the analysis was performed on the
ITT population. The differences in the Hb-AUC5)16 between
the two treatment groups were similar across the three
types of lymphoproliferative malignancies investigated
(Table III).
Response rate and time to response
The proportion of patients who responded to treatment was
similar in both groups (72 vs 75% for q.w. vs t.i.w. dosing,
ITT population). Median time to response was 71 d for the
q.w. group and 57 d for the t.i.w. group (P ¼ 0Æ57).
Haemoglobin nadirs and correction of anaemia
Mean Hb nadir values were determined over 4-week
intervals and are presented in Fig 2 (ITT population).
Values were similar for both groups throughout the study
period. Confidence intervals (90%) were largely within the
range of )0Æ5 to + 0Æ5, ruling out the possibility of a
significant difference between treatment groups.
Correction of anaemia (defined as a Hb nadir ‡11 or
‡12 g/dl in a 4-week interval) was achieved in 79% and
81% of patients (Hb ‡ 11 g/dl) and 60% and 64% of
patients (Hb ‡ 12 g/dl) in the q.w. and t.i.w. groups
respectively (ITT population).
Blood transfusions
Mean Hb values before blood transfusion were the same for
both groups (7Æ4 g/dl), and the overall incidence of trans-
fusion in the study was low (11% of patients). The
percentage of patients receiving at least one transfusion
was marginally lower in the q.w. group (9%) compared with
the t.i.w. group (14%) but this difference was not significant
(Cochrane–Maentel–Haenzel test, P ¼ 0Æ14 adjusted for
underlying disease).
Analysis of transfusion-free or severe anaemia-free sur-
vival confirmed that the number of patients requiring
transfusions was low and that the rates were similar






Male 55 (47) 47 (39)
Female 63 (53) 72 (61)
Age, years; median (range) 67 (38–82) 65 (33–90)
Body weight, kg, mean ± SD 68Æ6 ± 12Æ3 66Æ9 ± 13Æ8
Tumour classification
MM 78 (66) 80 (67)
NHL 16 (14) 16 (14)
CLL 24 (20) 23 (19)
Haemoglobin (g/dl), mean ± SD 10Æ2 ± 1Æ0 10Æ1 ± 1Æ0
Serum Epo (mU/ml); median (range) 41 (5–97) 41 (6–97)
Serum ferritin (lg/l); median (range) 245 (12–1342) 223 (1–1820)
No chemotherapy prior to epoetin beta therapy 39/118 (33) 38/119 (32)
No chemotherapy concurrent with epoetin beta therapy 13/118 (11) 19/119 (16)
No chemotherapy at all 2/118 (2) 4/119 (3)
CLL, chronic lymphocytic leukaemia; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma.
Fig 1. Time course of mean haemoglobin (Hb) level in anaemic
patients with lymphoproliferative malignancies treated with epoetin
beta 30 000 IU q.w. (n ¼ 101) or 10 000 IU t.i.w. (n ¼ 104) (PP
population).
Epoetin beta for Treatment of Anaemic Patients with Lymphoproliferative Malignancy 389
 2003 Blackwell Publishing Ltd, British Journal of Haematology 122: 386–393
between the two groups (Cox regression analysis adjusted
for underlying malignant disease, P ¼ 0Æ50).
Epoetin beta doses, iron supplementation and safety
The mean weekly epoetin beta dose between weeks 5 and
16 was 323 IU/kg in the once-weekly group and 267 IU/kg
in the thrice-weekly group (ITT). Therefore, the once-
weekly to thrice-weekly dose ratio during this period was
1Æ21 (95% CI 0Æ90; 1Æ61). The observed difference could be
attributed to the small CLL subgroup (24 vs 24 patients,
ratio 2Æ29), while no difference was observed in the majority
of patients with multiple myeloma or NHL (95 vs 98
patients, ratio 1Æ02). The difference observed in the small
CLL subgroup was determined by the fact that a few patients
receiving epoetin beta thrice weekly achieved a response
quickly, which was maintained with low doses of the drug.
Overall, there was a decrease in the median and mean
weekly dose per kg in both treatment groups by week 8 to
the end of the study in both the PP and the ITT population.
Similar proportions of patients needed i.v. (44% vs 39%)
and oral (75% vs 67%) iron supplementation in the q.w.
and the t.i.w. group respectively.
Treatment with epoetin beta was well tolerated. Eighty-
four patients (71%) in each treatment group reported at
least one adverse event. Only 12 patients (10%) in the q.w.
and 22 patients (18%) in the t.i.w. group were considered to
have treatment-related adverse events. The most common
adverse events for the q.w. and t.i.w. groups were infections
(37% vs 38%), gastrointestinal disorders (31% vs 31%),
general disorders (16% vs 18%) and vascular disorders
(15% vs 18%).
Evaluation of anti-Epo antibodies was planned at baseline
and during week 17 of study. All of the 118 patients in the
once-weekly group and 119 in the thrice-weekly group that
were analysed were negative for antiepoetin beta antibodies.
Predictors and early indicators of response to epoetin beta
Both baseline clinical parameters and changes in clinical
parameters early in the study period were assessed for
predictive power of response to epoetin beta. At baseline,
serum Epo level (P ¼ 0Æ002) was found to be predictive of
response (Table IV). Changes in Hb between weeks 1 and 3
(P < 0Æ00001), and changes from baseline in sTfR levels in
weeks 2 and 3 (P < 0Æ01) were found to be early indicators
of response.
DISCUSSION
This study is the first to investigate the relative efficacy and
safety of q.w. and t.i.w. epoetin regimens in a powered
comparison. Its results demonstrate that epoetin beta given
once weekly is as effective and well tolerated as a three-
times-weekly schedule in treating anaemic patients with
lymphoproliferative disorders and reduced endogenous Epo
production.
The current study was designed to test the hypothesis
that epoetin beta given once weekly was not inferior to the
Table III. Change in the area under the haemoglobin–time curve between weeks5 and 16 (Hb-AUC5)16) in
anaemic patients with lymphoproliferative malignancies treated with epoetin beta 30 000 IU q.w. or
10 000 IU t.i.w. (per protocol population).
Mean Hb-AUC (g/dl)
Difference (90% CI)30 000 IU q.w. 10 000 IU t.i.w.
Total population* 12Æ05 12Æ27 )0Æ22 ()0Æ53, 0Æ10)
Multiple myeloma 12Æ11 12Æ25 )0Æ14 ()0Æ49, 0Æ21)
Non-Hodgkin’s lymphoma 11Æ51 12Æ13 )0Æ62 ()1Æ81, 0Æ56)
Chronic lymphocytic leukaemia 12Æ32 12Æ54 )0Æ21 ()1Æ03, 0Æ61)
*Per protocol (PP) population.
Intent-to-treat (ITT) population.
CI, confidence interval.
Fig 2. Mean haemoglobin (Hb) nadir at 4-weekly intervals in
anaemic patients with lymphoproliferative malignancies treated
with epoetin beta 30 000 IU q.w. (n ¼ 115) or 10 000 IU t.i.w.
(n ¼ 114) (ITT population).
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three-times weekly schedule with respect to several import-
ant clinical parameters. The primary efficacy parameter of
the study was the time-adjusted area under the Hb–time
curve (Hb AUC5)16). The q.w. regimen was clinically
comparable to the t.i.w. regimen, as the two curves were
virtually identical. Furthermore, the difference in Hb
AUC5)16 between the two groups did not exceed 0Æ6 g/dl
at any time during the study. The remaining clinical
parameters examined in this study (Hb nadirs, response
rates and transfusion requirements) confirmed these data.
In the assessment of equivalence in mean weekly epoetin
doses, a difference of 21% (once-weekly to thrice-weekly
dose ratio equal to 1Æ21) was recorded between the two
treatment groups between weeks 5 and 16. This ratio
remained within the prespecified equivalence range. More-
over, the observed difference could be attributed to a small
portion of patients with CLL who responded quickly to
epoetin beta administered thrice weekly. No difference at all
(i.e. 2%) was observed in the vast majority of patients
(n ¼ 193) with multiple myeloma or NHL.
A previous study has examined the effect of a once-
weekly epoetin regimen on Hb levels, transfusion require-
ments and quality of life in patients with solid and
haematological malignancies (Gabrilove et al, 2001). This
study showed that a dose of 40 000 IU once weekly
provided improvements in haemoglobin and quality of life
similar to the conventional thrice weekly dosing
(3 · 10 000 IU). However, this study had many potential
flaws (Nguyen & Trinh 2002): (a) it was non-randomized
and compared the once-weekly results with those of
historical, rather than parallel, control subjects receiving
epoetin t.i.w.; (b) there was no adjustment for potential
baseline confounding variables and for handling of the
relatively large dropout rate; (c) different weekly doses of
epoetin alpha (40 000 in q.w. group vs 30 000 in t.i.w.
group) were compared. In contrast, the current study was
randomized, and directly compared results between patients
receiving identical doses of epoetin beta (30 000 IU) q.w. or
t.i.w., thus producing a more robust assessment. The results
are consistent with those of recent randomized trials of
epoetin beta in the maintenance treatment of renal
anaemia, which demonstrated that the efficacies of once
weekly and three times weekly epoetin beta regimens are
equivalent (Weiss et al, 2000; Locatelli et al, 2002).
The efficacy of the once-weekly regimen is in agreement
with the physiological role of Epo in erythropoiesis. In fact,
Epo mainly acts as a survival factor for erythroid progen-
itors, which require the continual presence of small doses of
the hormone to survive (Koury & Bondurant, 1990a; Kelley
et al, 1993). In this model of erythropoiesis based on Epo
prevention of programmed cell death, erythropoiesis can be
substantially and steadily expanded only through
preamplification of Epo-dependent progenitors (Koury &
Bondurant, 1990b). When endogenous Epo levels are
inappropriately low, administration of epoetin can be
effective in allowing the survival of more erythroid
progenitors and the generation of erythroid precursors that
subsequently mature to red cells. The results of the present
study indicate that this can be effectively achieved with the
once-weekly subcutaneous administration of epoetin beta.
Despite the success of epoetin in treating anaemia in both
the haemodialysis and cancer settings, outside the setting of
uraemia, a variable portion of patients do not respond to
epoetin therapy (Cazzola et al, 1997). Attempts have been
made to identify those patients most likely to respond to
therapy. In this study, the number of patients who
responded to epoetin beta treatment was high in both arms
(75%). This is probably attributable to the strict inclusion
criteria of the trial, whereby only patients with defective
endogenous Epo production, as indicated by serum Epo
levels £100 mU/ml, were enrolled. In clinical practice, a
serum Epo level < 100 mU/ml in an anaemic patient can be
taken as an indicator of reduced serum Epo production and
a strong predictor of response to epoetin treatment (Beguin,
2002). It must be stressed that, even in this selected
population of patients with low serum Epo, this latter
parameter was found to be a strong predictor of response
(Table IV). This also indicates that, in patients with defect-
ive endogenous Epo production, the lower the serum Epo,
the higher the likelihood of response.
Tailoring epoetin use to patients with a high probability
of response, i.e. improving the prediction of response, is
one of the major ways of making epoetin treatment cost-
effective (Barosi & Marchetti, 2000). Therefore, in patients
Table IV. Baseline predictors and early treatment indicators of response to epoetin beta.
Hazard ratio (95% CI) P-value
Baseline
Haemoglobin, g/dl 0Æ884 (0Æ756–1Æ035) 0Æ125
Serum creatinine, mmol/l 1Æ000 (0Æ996–1Æ003) 0Æ881
Serum Epo (mU/ml) 0Æ989 (0Æ982–0Æ996) 0Æ002
Early treatment
Hb increase from week 1–3 (0Æ1 g/dl) 1Æ053 (1Æ038–1Æ069) < 0Æ00001
sTfR level increase from baseline
> 15% vs £ 15% 1Æ604 (1Æ137–2Æ265) 0Æ007
> 20% vs £ 20% 1Æ635 (1Æ178–2Æ270) 0Æ003
> 25% vs £ 25% 1Æ695 (1Æ238–2Æ322) 0Æ001
sTfR, soluble transferrin receptor.
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with lymphoproliferative disorders, limiting epoetin admin-
istration to those who show defective endogenous Epo
production represents a rational use of the recombinant
hormone from both a medical (Pangalis et al, 2002) and
community perspective (Barosi & Marchetti, 2000). In this
study, for instance, about 25% of patients initially
screened for serum Epo had values > 100 mU/ml (Table I)
and were excluded from treatment. A small portion of
patients, however, in spite of their low serum Epo levels
(< 100 mU/ml), did not respond to epoetin beta: further
characterization of predictors of non-response is required
as this might further improve the cost effectiveness of
epoetin therapy.
Incidences of adverse events during the study were
similar for both regimens, and the incidence of those that
could be directly related to epoetin beta was very low. More
importantly, no patient enrolled in the study developed anti-
Epo antibodies. It has recently been noted that some dialysis
patients treated with epoetin have developed pure red cell
aplasia through the production of neutralizing anti-Epo
antibodies (Casadevall et al, 2002). This complication
appears to be linked to a particular epoetin formulation
(Gershon et al, 2002), and whether it can also occur outside
nephrology is unclear at present. A close laboratory
monitoring of patients receiving epoetin therapy is, there-
fore, recommended (Cavill & Williams, 2002).
In conclusion, epoetin beta given q.w. is comparable to
the established t.i.w. regimen and, therefore, represents an
effective and safe treatment for anaemia in patients with
lymphoproliferative malignancy and defective endogenous
Epo production. Self-administration at home of the same
quantity of epoetin beta in a single weekly injection with no
loss of efficacy will undoubtedly help to produce substantial
cost savings (Besarab et al, 2002). Using this method of
administration and tailoring treatment to subjects with
defective endogenous Epo production represents a rational
use of epoetin from a medical and a community perspective.
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